5 patents
Utility
Antibodies that bind EGFR and ErbB3
23 Nov 20
The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 pM for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells.
Ton Logtenberg, Mark Throsby, Robertus Cornelis Roovers
Filed: 26 Feb 15
Utility
Methods and means for the production of ig-like molecules
24 Aug 20
The invention provides means and methods for producing one or more Ig-like molecules in a single host cell.
Cornelis Adriaan De Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
Filed: 19 May 19
Utility
Method for selecting a single cell expressing a heterogeneous combination of antibodies
1 Jun 20
The present invention provides combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other.
Hendricus Renerus Jacobus Mattheus Hoogenboom, Ton Logtenberg
Filed: 20 Aug 17
Utility
Generation of binding molecules
11 May 20
Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy.
Mark Throsby, Ton Logtenberg, John De Kruif
Filed: 21 Nov 17
Utility
Antibody producing non-human animals
30 Mar 20
Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain.
Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. Dekruif, Erwin Houtzager
Filed: 26 Apr 16
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first